Prevalence and molecular characterization of common thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province in Southwestern China

Figures & data

Figure 1. (A) The prevalence of common thalassemia; (B) The prevalence of α-thalassemia, β-thalassemia, and concurrent α- and β-thalassemia; (C) The constituent ratio of α-thalassemia, β-thalassemia, and concurrent α- and β-thalassemia.

Table 1. Genotyping of α-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China.

Genotype	Phenotype	No. patients detected	Constituent ratio (%)
^--^SEA/αα	α^0/α	6357	46.76
-α^3.7/αα	α^+/α	2786	20.49
α^CSα/αα	α^+/α	1433	10.54
-α^4.2/αα	α^+/α	973	7.16
α^WSα/αα	α^+/α	664	4.88
^--^SEA/-α^3.7	α^0/α^+	304	2.24
^--^SEA/α^CSα	α^0/α^+	157	1.15
α^QSα/αα	α^+/α	128	0.94
-α^3.7/-α^3.7	α^+/α^+	124	0.91
^--^SEA/-α^4.2	α^0/α^+	119	0.88
^--^SEA/α^WSα	α^0/α^+	116	0.85
-α^3.7α/α^CSα	α^+/α^+	102	0.75
-α^3.7/-α^4.2	α^+/α^+	82	0.60
-α^3.7α/α^WSα	α^+/α^+	59	0.43
α^CSα/α^CSα	α^+/α^+	42	0.31
-α^4.2α/α^WSα	α^+/α^+	39	0.29
-α^4.2α/α^CSα	α^+/α^+	35	0.26
α^WSα/α^CSα	α^+/α^+	29	0.21
-α^3.7α/α^QSα	α^+/α^+	12	0.09
-α^4.2/-α^4.2	α^+/α^+	12	0.09
^--^SEA/α^QSα	α^0/α^+	8	0.06
α^CSα/α^QSα	α^+/α^+	8	0.06
-α^4.2α/α^QSα	α^+/α^+	4	0.03
α^WSα/α^WSα	α^+/α^+	2	0.01
α^QSα^/α^QSα	α^+/α^+	1	0.01
Subtotal	–	13596	100

α⁰, indicates absent synthesis of α-globin peptide chain; α⁺, indicates reduced synthesis of α-globin peptide chain; α, indicates no mutation.

Table 2. Genotyping of β-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China.

Genotype	Phenotype	No. patients detected	Constituent ratio (%)
β^CD17/β^N	β^0/β^N	2332	43.39
β^CD41-42/β^N	β^0/β^N	1794	33.38
β^CD26/β^N	Hb E	328	6.10
β^IVS-I-1/β^N	β^0/β^N	264	4.91
β^-28/β^N	β^+/β^N	210	3.91
β^CD71-72/β^N	β^0/β^N	204	3.80
β^IVS-II-654/β^N	β^+/β^N	152	2.83
β^CD43/β^N	β^0/β^N	44	0.82
β^-29/β^N	β^+/β^N	36	0.67
β^CD 27-28/β^N	β^0/β^N	6	0.11
β^CD14-15/β^N	β^0/β^N	1	0.02
β^CAP/β^N	β^+/β^N	1	0.02
β^-28/β^CD17	β^+/β^0	1	0.02
β^-28/β^CD41-42	β^+/β^0	1	0.02
β^-28/β^IVS-I-1	β^+/β^0	1	0.02
Subtotal	–	5375	100

β⁰, absent synthesis of β-globin peptide chain; β⁺, reduced synthesis of β-globin peptide chain; N, no mutation.

Table 3. Genotyping of concurrent α- and β-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China.

Genotype	Phenotype	No. patients detected	Constituent ratio (%)
^--^SEA/αα/β^CD17/β^N	α^0/α/β^0/β^N	253	14.06
^--^SEA/αα/β^CD41-42/β^N	α^0/α/β^0/β^N	217	12.06
-α^3.7/αα/β^CD17/β^N	α^+/α/β^0/β^N	182	10.12
-α^3.7/αα/β^CD41-42/β^N	α^+/α/β^0/β^N	176	9.78
α^CSα/αα/β^CD17/β^N	α^+/α/β^0/β^N	101	5.61
α^CSα/αα/β^CD41-42/β^N	α^+/α/β^0/β^N	82	4.56
-α^4.2/αα/β^CD17/β^N	α^+/α/β^0/β^N	76	4.22
α^WSα/αα/β^CD41-42/β^N	α^+/α/β^0/β^N	71	3.95
α^WSα/αα/β^CD17/β^N	α^+/α/β^0/β^N	65	3.61
^--^SEA/αα/β^CD26/β^N	α^0/α/Hb E	50	2.78
-α^4.2/αα/β^CD41-42/β^N	α^+/α/β^0/β^N	48	2.67
^--^SEA/αα/β^-28/β^N	α^0/α/β^+/β^N	31	1.72
^--^SEA/αα/β^IVS-I-1/β^N	α^0/α/β^0/β^N	28	1.56
-α^3.7/αα/β^CD26/β^N	α^+/α/Hb E	26	1.45
-α^3.7/αα/β^IVS-I-1/β^N	α^+/α/β^0/β^N	24	1.33
^--^SEA/αα/β^CD71-72/β^N	α^0/α/β^0/β^N	22	1.22
-α^3.7/αα/β^CD71-72/β^N	α^+/α/β^0/β^N	22	1.22
^--^SEA/-α^3.7/β^CD17/β^N	α^0/α^+/β^0/β^N	18	1.00
^--^SEA/αα/β^IVS-II-654/β^N	α^0/α/β^+/β^N	16	0.89
-α^3.7/αα/β^IVS-II-654/β^N	α^+/α/β^+/β^N	15	0.83
-α^3.7/αα/β^-28/β^N	α^+/α/β^+/β^N	14	0.78
α^WSα/αα/β^CD71-72/β^N	α^+/α/β^0/β^N	13	0.72
α^WSα/αα/β^CD26/β^N	α^+/α/Hb E	12	0.67
^--^SEA/-α^3.7/β^CD41-42/β^N	α^0/α^+/β^0/β^N	11	0.61
α^CSα/αα/β^IVS-I-1/β^N	α^+/α/β^0/β^N	11	0.61
-α^4.2/αα/β^CD26/β^N	α^+/α/Hb E	9	0.50
-α^4.2/αα/β^CD71-72/β^N	α^+/α/β^0/β^N	9	0.50
α^CSα/αα/β^-28/β^N	α^+/α/β^+/β^N	9	0.50
-α^3.7/-α^3.7/β^CD17/β^N	α^+/α^+/β^0/β^N	8	0.44
-α^3.7α/α^CSα/β^CD41-42/β^N	α^+/α^+/β^0/β^N	8	0.44
α^CSα/αα/β^CD71-72/β^N	α^+/α/β^0/β^N	8	0.44
α^CSα/αα/β^IVS-II-654/β^N	α^+/α/β^+/β^N	8	0.44
-α^3.7α/α^CSα/β^CD41-42/β^N	α^+/α^+/β^0/β^N	7	0.39
-α^3.7α/α^WSα/β^CD41-42/β^N	α^+/α^+/β^0/β^N	7	0.39
-α^3.7α/α^CSα/β^IVS-I-1/β^N	α^+/α^+/β^0/β^N	7	0.39
Remaining 60 genotypes	–	135	7.50
Subtotal	–	1799	100

Table 4. Forms of thalassemia for which fetuses would be at risk among couples in which both partners were positive for thalassemia in isotype among people of reproductive age in the Border Area of Guangxi-Yunnan-Guizhou province, Southwestern China.

Major classes	Genotypes	No. couples detected
Hb Bart's	--/--	808
HbH	--/-α	1019
HbH	--/α^Tα	681
HbH or TMN	α^Tα/α^Tα	149
TMN	-α/-α	350
TMN	-α/α^Tα	407
TM or TI	β^0/β^0	627
TM or TI	β^+/β^0	97
TM or TI	β^+/β^+	6
TM or TI	HbE/HbE	4
TM or TI	HbE/β^0	65
TM or TI	HbE/β^+	8

Abbreviations: Hb Bart’s, Hb Bart’s hydrops fetalis; HbH, Hb H disease; TMN, thalassemia minor; TM, thalassemia major; TI, thalassemia intermedia.

Figure 2. Hematological characterization of α-thalassemia among different genders and genotypes. (A) MCV levels among participants with different genders and genotypes; (B) MCH levels among participants with different genders and genotypes; (C) Hb levels among participants with different genders and genotypes; (D) HbA2 levels among participants with different genders and genotypes; (E) HbF levels among participants with different genders and genotypes. ^# Males had significantly higher levels (p < 0.05) than females in the same genotypic group, * Males had significantly lower levels (p < 0.05) than females in the same genotypic group. P values for significant differences (p < 0.05) between genotypes of α-thalassaemia are shown. Non-listed comparisons are not significant.

Table 5. Characteristics and hematological parameters of α-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China, M (P25, P75).

Genotype	Gender (cases)	MCV (fl)	MCH (Pg)	Hb (g/dl)	HbA2 (%)	HbF (%)
^--^SEA/αα	M (3187)	69.80 (67.50,72.50)	21.70 (20.80, 22.60)	13.80 (13.20, 14.50)	2.40 (2.30, 2.60)	0.40 (0.23, 0.80)
	F (3170)	68.30 (66.00, 70.80)	21.30 (20.50, 22.10)	11.00 (10.40, 11.60)	2.50 (2.30, 2.60)	0.50 (0.30, 0.79)
-α^3.7/αα	M (1367)	83.65 (81.00, 86.27)	26.55 (25.82, 27.50)	14.80 (14.10, 15.30)	2.60 (2.40, 2.80)	0.30 (0.20, 0.55)
	F (1419)	82.00 (79.85, 84.80)	26.60 (25.67, 27.30)	11.90 (11.20, 12.50)	2.60 (2.40, 2.80)	0.40 (0.30, 0.60)
α^CSα/αα	M (669)	82.70 (80.42, 84.90)	26.30 (25.60, 27.00)	14.60 (14.00, 15.20)	2.40 (2.30, 2.50)	0.40 (0.30, 0.70)
	F (764)	82.40 (80.00, 85.00)	26.20 (25.30, 27.10)	11.60 (11.10, 12.40)	2.40 (2.20, 2.60)	0.50 (0.40, 0.90)
-α^4.2/αα	M (492)	83.40 (81.90, 85.17)	26.70 (26.10, 27.40)	14.80 (14.20, 15.40)	2.50 (2.40, 2.60)	0.40 (0.30, 0.50)
	F (481)	82.03 (79.40, 85.00)	26.50 (25.50, 27.24)	11.90 (11.31, 12.50)	2.60 (2.40, 2.80)	0.40 (0.30, 0.73)
α^WSα/αα	M (340)	85.30 (81.90, 88.00)	27.36 (26.20, 28.80)	15.00 (14.43, 15.80)	2.75 (2.43, 3.00)	0.40 (0.30, 0.60)
	F (324)	83.40 (80.45, 86.60)	27.00 (26.00, 28.00)	12.00 (11.20, 12.60)	2.80 (2.70, 3.00)	0.40 (0.30, 0.70)
^--^SEA/-α^3.7	M (141)	60.60 (58.80, 67.00)	17.90 (17.00, 19.00)	11.00 (10.35, 11.50)	1.60 (1.40, 1.80)	0.50 (0.20, 0.70)
	F (163)	63.00 (57.38, 66.15)	18.30 (17.10, 19.03)	8.70 (8.13, 9.30)	1.65 (1.35, 1.95)	0.30 (0.20, 0.98)
^--^SEA/α^CSα	M (62)	75.05 (70.00, 78.18)	19.60 (19.00, 20.85)	9.40 (8.37, 10.05)	1.15 (0.88, 1.45)	0.35(0.20, 0.43)
	F (95)	74.60 (69.70, 76.90)	18.90 (17.80, 19.75)	7.70 (6.95, 8.17)	1.30 (1.20, 1.85)	0.70 (0.35, 1.05)
α^QSα/αα	M (72)	81.20 (78.00, 84.18)	25.40 (24.4, 25.65)	14.40 (13.47, 14.88)	2.55 (2.50, 2.70)	0.40 (0.33, 0.78)
	F (56)	75.40 (73.50, 77.00)	23.81 (23.10, 25.00)	11.60 (11.00, 12.31)	2.60 (2.50, 2.80)	0.50 (0.40, 0.90)
-α^3.7/-α^3.7	M (61)	77.05 (73.72, 80.58)	23.40 (22.60, 26.30)	13.60 (12.90, 14.70)	2.65 (2.47, 2.70)	0.45 (0.38, 0.73)
	F (63)	72.00 (68.10, 73.80)	22.60 (21.00, 23.75)	11.70 (10.95, 12.05)	2.60 (2.50, 2.75)	0.70 (0.55, 0.90)
^--^SEA/-α^4.2	M (55)	61.20 (60.40, 64.30)	18.50 (18.35, 18.85)	11.60 (10.45, 12.00)	1.60 (1.50, 1.75)	0.60 (0.35, 0.75)
	F (64)	60.80 (59.38, 63.88)	18.00 (17.28, 18.78)	8.65 (7.98, 9.33)	1.55 (1.50, 1.80)	0.70 (0.38, 1.18)
^--^SEA/α^WSα	M (59)	66.80 (66.00, 69.23)	20.95 (19.80, 22.00)	13.15 (12.75, 13.55)	2.40 (2.20, 2.68)	0.35 (0.23, 0.50)
	F (57)	67.30 (63.52, 70.90)	19.90 (18.70, 22.00)	11.30 (10.20, 11.70)	2.60 (2.45, 2.70)	0.40 (0.25, 0.60)
-α^3.7α/α^CSα	M (49)	78.95 (75.48, 84.23)	23.50 (22.80, 25.18)	13.00 (12.58, 13.50)	2.60 (2.35, 2.60)	0.30 (0.20, 0.93)
	F (53)	76.00 (68.30, 81.00)	22.50 (21.30, 24.90)	10.05 (9.90, 10.60)	2.50 (2.30, 2.80)	0.70 (0.40, 1.30)
-α^3.7/-α^4.2	M (48)	78.00 (71.10, 83.25)	24.00 (22.85, 26.70)	14.30 (13.45, 15.25)	2.50 (2.20, 2.60)	0.40 (0.25, 0.65)
	F (34)	73.50 (71.23, 76.00)	23.15 (22.43, 23.97)	11.03 (9.98, 11.29)	2.50 (2.40, 2.58)	0.40 (0.33, 0.50)
-α^3.7α/α^WSα	M (24)	78.00 (70.83, 83.90)	26.00 (21.00, 26.28)	14.10 (13.43, 14.48)	2.30 (2.18, 2.55)	0.40 (0.20, 0.60)
	F (35)	68.50 (66.88, 72.03)	21.80 (20.68, 22.68)	11.50 (10.38, 12.23)	2.50 (2.28, 2.70)	0.40 (0.28, 0.75)
α^CSα/α^CSα	M (22)	84.00 (77.80, 85.40)	24.20 (22.80, 26.10)	11.60 (10.20, 13.20)	1.60 (1.50, 1.80)	0.70 (0.20, 1.10)
	F (20)	81.40 (78.48, 86.08)	25.50 (23.98, 25.88)	9.20 (8.88, 10.65)	1.60 (1.25, 2.13)	0.60 (0.38, 1.20)
-α^4.2α/α^WSα	M (22)	79.60 (77.40, 81.25)	25.00 (23.28, 25.60)	14.05 (13.55, 14.63)	2.35 (2.23, 2.58)	0.55 (0.30, 1.05)
	F (17)	72.90 (71.39, 74.00)	22.40 (22.30, 23.00)	10.80 (10.60, 10.90)	2.50 (2.40, 2.60)	0.60 (0.30, 1.10)
-α^4.2α/α^CSα	M (13)	80.50 (79.00, 81.33)	24.10 (23.33, 24.60)	13.60 (12.75, 14.50)	2.30 (2.18, 2.43)	0.60 (0.35, 0.93)
	F (22)	72.14 (70.65, 80.48)	22.35 (20.98, 24.50)	10.75 (10.35, 10.97)	2.30 (2.02, 2.73)	0.75 (0.33, 1.03)
α^WSα/α^CSα	M (14)	80.40 (79.18, 81.78)	25.50 (23.50, 26.68)	14.65 (13.58, 15.20)	2.45 (2.18, 2.58)	0.45 (0.23, 0.98)
	F (15)	80.50 (73.40, 86.40)	24.50 (23.30, 26.20)	11.45 (10.80, 12.10)	2.60 (2.20, 2.70)	0.65 (0.20, 1.10)

Abbreviations: M, Male; F, Female.

Figure 3. Hematological characterization of β-thalassemia among different genders and genotypes. (A) MCV levels among participants with different genders and genotypes; (B) MCH levels among participants with different genders and genotypes; (C) Hb levels among participants with different genders and genotypes; (D) HbA2 levels among participants with different genders and genotypes; (E) HbF levels among participants with different genders and genotypes. ^# Males had significantly higher levels (p < 0.05) than females in the same genotypic group, * Males had significantly lower levels (p < 0.05) than females in the same genotypic group. P values for significant differences (p < 0.05) between genotypes of β-thalassaemia are shown. Non-listed comparisons were not significant. The HbA2% level of genotype β^CD26/β^N was the sum of HbA2% and HbE%, and was not compared with other genotypes.

Table 6. Characteristics and hematological parameters of β-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China, M (P25, P75).

Genotype	Gender (cases)	MCV (fl)	MCH (Pg)	Hb (g/dl)	HbA2 (%;)	HbF (%)
β^CD17/β^N	M (1135)	64.30 (61.50, 67.91)	20.10 (19.20, 21.30)	13.10 (12.40, 13.87)	5.40 (5.10, 5.70)	1.00 (0.60, 1.39)
	F (1197)	64.60 (61.90, 67.40)	20.20 (19.40, 21.20)	10.40 (9.62, 11.10)	5.40 (5.10, 5.70)	1.40 (0.80, 2.39)
β^CD41-42/β^N	M (881)	65.20 (62.71, 68.78)	20.30 (19.40, 21.40)	13.20 (12.40, 13.90)	5.40 (5.10, 5.70)	0.80 (0.40, 1.40)
	F (913)	65.00 (62.10, 67.70)	20.30 (19.40, 21.23)	10.30 (9.60, 11.00)	5.30 (5.05, 5.60)	1.00 (0.70, 1.90)
β^CD26/β^N	M (153)	78.00 (73.35, 80.15)	25.27 (24.60, 26.25)	14.20 (13.28, 14.86)	25.35 (23.53, 26.90)	0.90 (0.55, 1.55)
	F (175)	76.35 (68.43, 78.55)	25.25 (23.90, 26.30)	11.50 (10.75, 12.25)	26.00 (22.10, 28.05)	0.90 (0.58, 1.45)
β^IVS-I-1/β^N	M (134)	65.53 (63.08, 67.93)	20.70 (19.80, 21.85)	13.20 (12.68, 13.85)	5.20 (4.90, 5.40)	1.00 (0.40, 1.30)
	F (130)	65.70 (63.60, 69.07)	20.45 (19.70, 21.95)	10.70 (9.85, 10.98)	5.20 (4.80, 5.60)	1.20 (0.80, 1.85)
β^CD71-72/β^N	M (90)	64.60 (63.40, 69.15)	19.70 (19.00, 21.05)	12.60 (12.00, 13.35)	5.20 (4.90, 5.50)	0.80 (0.40, 0.90)
	F (114)	65.70 (62.30, 68.00)	20.60 (19.20, 21.33)	10.50 (9.70, 11.10)	5.50 (5.10, 5.60)	0.70 (0.60, 1.00)
β^-28/β^N	M (109)	73.75 (71.00, 76.00)	23.30 (22.50, 23.72)	14.30 (13.28, 14.90)	5.30 (4.90, 5.50)	0.90 (0.60, 1.81)
	F (101)	72.00 (69.13, 74.63)	23.00 (21.68, 23.55)	10.95 (10.48, 11.65)	5.40 (4.90, 5.60)	1.60 (1.20, 2.30)
β^IVS-II-654/β^N	M (81)	63.80 (62.45, 68.45)	19.70 (19.05, 21.25)	13.40 (12.70, 13.90)	5.50 (4.50, 5.80)	0.70 (0.50, 0.90)
	F (71)	64.15 (61.10, 66.13)	20.08 (18.93, 21.15)	10.60 (9.58, 11.50)	5.00 (4.90, 5.30)	1.00 (0.70, 1.50)
β^CD43/β^N	M (19)	65.00 (63.80, 68.00)	21.65 (20.70, 22.40)	13.25 (12.90, 13.60)	5.25 (5.00, 6.10)	0.65 (0.60, 0.90)
	F (25)	65.90 (60.47, 66.50)	19.50 (18.48, 21.20)	10.20 ( (9.00, 10.70)	5.50 (5.30, 5.70)	0.90 (0.50, 1.10)
β^-29/β^N	M (18)	69.30 (67.80, 70.00)	23.90 (22.70, 24.00)	13.30 (13.10, 13.70)	5.30 (5.10, 5.60)	0.70 (0.40, 0.90)
	F (18)	67.90 (64.20, 75.20)	24.30 (21.00, 25.60)	11.65 (10.80, 12.40)	5.65 (4.90, 5.90)	0.80 (0.60, 1.20)

The HbA2% level of genotype β^CD26/β^N was actually the sum of HbA2% and HbE%.

Figure 4. Hematological characterization of concurrent α- and β-thalassemia among different genders and genotypes. (A) MCV levels among participants with different genders and genotypes; (B) MCH levels among participants with different genders and genotypes; (C) Hb levels among participants with different genders and genotypes; (D) HbA2 levels among participants with different genders and genotypes; (E) HbF levels among participants with different genders and genotypes. ^#Males had significantly higher levels (p < 0.05) than females in the same genotypic group; ^△Compared to β-thalassemia alone group in the same gender, concurrent α- and β-thalassemia group had significantly higher levels (p < 0.05); ^⋆compared to α-thalassemia alone group in the same gender, concurrent α- and β-thalassemia group had significantly higher levels (p < 0.05). ^▴Compared to β-thalassemia alone group in the same gender, concurrent α- and β-thalassemia group had significantly lower levels (p < 0.05); ^★compared to the α-thalassemia alone group in the same gender, concurrent α- and β-thalassemia group had significantly lower levels (p < 0.05). Non-listed comparisons were not significant. The HbA2% level of genotype ^--SEA/αα/β^CD26/β^N was the sum of HbA2% and HbE%, and was not compared with other genotypes except, β^CD26/β^N.

Table 7. Characteristics and hematological parameters of concurrent α- and β-thalassemia among people of reproductive age in the border area of Guangxi-Yunnan-Guizhou province, Southwestern China, M (P25, P75).

Genotype	Gender	MCV (fl)	MCH (Pg)	Hb (g/dl)	HbA2 (%;)	HbF (%;)
^--^SEA/αα/β^CD17/β^N	M (118)	70.15 (68.15, 72.35)	22.00(21.48, 23.18)	14.00 (13.55, 14.75)	5.60 (4.95, 6.00)	0.60 (0.30, 1.30)
	F (135)	69.20 (67.80, 71.35)	21.90 (21.40, 22.65)	11.20 (10.65, 11.70)	5.50 (5.20, 6.00)	0.70 (0.60, 1.06)
^--^SEA/αα/β^CD41-42/β^N	M (113)	72.55 (69.10, 77.03)	22.85 (21.95, 24.13)	14.50 (13.78, 14.98)	5.40 (5.03, 5.70)	0.55 (0.33, 0.78)
	F (104)	71.90(67.58, 75.28)	22.35 (21.34, 23.71)	11.10 (10.56, 11.90)	5.30 (5.13, 5.63)	0.90(0.60, 1.45)
-α^3.7/αα/β^CD17/β^N	M (97)	68.00 (64.53, 71.28)	21.00 (19.85, 22.55)	13.30 (12.90, 13.78)	5.50 (5.40, 5.60)	0.90 (0.65, 1.10)
	F (85)	65.20 (63.75, 66.55)	20.45 (19.38, 21.18)	10.60 (9.80, 11.00)	5.80 (5.30, 5.90)	1.00 (0.60, 1.40)
-α^3.7/αα/β^CD41-42/β^N	M (87)	69.25 (65.15, 73.35)	21.30 (20.30, 22.60)	13.55 (12.98, 14.50)	5.35(5.18, 5.50)	0.80 (0.60, 1.18)
	F (89)	66.95 (64.53, 69.42)	20.90 (20.40, 21.38)	10.85(10.00, 11.19)	5.45 (5.30, 5.90)	0.85 (0.60, 1.35)
α^CSα/αα/β^CD17/β^N	M (58)	69.10 (66.05, 72.28)	21.45 (20.38, 22.53)	13.60 (12.98, 14.00)	5.20 (4.73, 5.48)	0.85 (0.60, 1.15)
	F (43)	67.20 (65.80, 70.33)	20.90 (20.10, 21.70)	10.90 (9.80, 11.20)	5.25 (4.85, 5.50)	1.05 (0.88, 1.23)
α^CSα/αα/β^CD41-42/β^N	M (36)	70.65 (66.58, 73.25)	21.95 (20.35, 22.95)	13.80 (13.53, 14.08)	5.10 (4.83, 5.38)	0.75 (0.53, 0.90)
	F (46)	68.70 (67.90, 70.80)	21.20 (20.80, 22.00)	10.90 (9.60, 11.50)	5.40 (5.10, 5.60)	0.90 (0.70, 1.10)
-α^4.2/αα/β^CD17/β^N	M (42)	66.90 (63.10, 69.83)	20.81 (19.78, 22.05)	13.27 (12.73, 13.58)	5.15 (4.63, 5.55)	0.70 (0.58, 1.10)
	F (34)	67.40 (66.30, 69.90)	21.10 (20.80, 22.20)	10.90 (10.40, 11.40)	5.40 (4.97, 5.50)	0.80 (0.60, 1.10)
α^WSα/αα/β^CD41-42/β^N	M (41)	68.60 (63.70, 70.70)	21.50 (20.00, 22.40)	13.40 (12.90, 13.80)	5.20 (5.00, 5.50)	0.70 (0.40, 0.80)
	F (30)	68.55 (64.39, 71.63)	21.25 (19.94, 22.52)	10.80 (9.69, 12.12)	5.10 (4.90, 5.50)	0.80 (0.50, 1.10)
α^WSα/αα/β^CD17/β^N	M (40)	68.55 (63.15, 72.28)	21.65 (20.03, 22.28)	13.60 (13.30, 14.30)	5.20(5.00, 5.50)	0.60 (0.30, 0.80)
	F (25)	68.57 (63.35, 70.70)	21.30 (19.65, 22.53)	10.90(10.35, 11.30)	5.30 (5.15, 5.55)	0.80 (0.45, 0.90)
^--^SEA/αα/β^CD26/β^N	M (23)	73.95 (70.50, 76.25)	23.80 (22.50, 25.48)	13.95(12.08, 14.53)	22.50 (22.20, 23.40)	0.50 (0.35, 0.85)
	F (27)	70.40 (68.00, 72.70)	22.40 (21.30, 24.59)	11.17 (10.50, 12.10)	22.60 (20.60, 24.60)	0.90 (0.60, 1.10)